학술논문

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
Document Type
Article
Author
Sands, B.E.Irving, P.M.Hoops, T.Izanec, J.L.Gao, L.-L.Gasink, C.Greenspan, A.Allez, M.Danese, S.Hanauer, S.B.Jairath, V.Kuehbacher, T.Lewis, J.D.Loftus, E.V.Mihaly, E.Panaccione, R.Scherl, E.Shchukina, O.B.Sandborn, W.J.Afzali, A.Aitova, L.Aldeguer i Mante, X.Altorjay, I.Argüelles Arias, F.Armuzzi, A.Augustyn, M.Bafutto, M.Barrio, J.Begun, J.Behrend, C.Bezemer, G.Bonnaud, G.Brankovic, M.Byung, I.J.Calvet Calvo, X.Chachu, K.Chebli, J.M.F.Cheon, J.H.Cichoz-Lach, H.Clark, L.Cummings, F.Dalal, K.De Boer, N.De Lourdes Ferrari, M.Désilets, E.Dugalic, P.Duvall, G.Fedorishina, O.Filip, R.Flores, C.Fogel, R.Fon, J.Frankel, M.Friedenberg, K.Fries, W.Galina, V.Gietka, P.Goel, R.Hasselblatt, P.Herfarth, H.Herszényi, L.Hindryckx, P.Hoentjen, F.Horjus Talabur Horje, C.Iduru, S.Isfort, R.Jones, M.Kalimullina, D.Katz, J.Kaur, M.Khurana, S.K.Kim, J.S.Kim, Y.Kleczkowski, D.Knezevic, S.Knoll, A.Korman, L.Y.Kotzev, I.Kulyapin, A.Lee, K.M.Leemreis, D.Leszczyszyn, J.Limdi, J.Lissauer, J.Loftus, E.Malecka-Panas, E.Marshall, J.Mihály, E.Milan, L.Monteleone, G.Nagorni, A.Owczarek, D.Palekar, N.Park, Y.S.Park, S.H.Parra, R.Patai, Á.Patel, K.Patel, B.Pershko, A.Petrova, E.Pineton de Chambrun, G.Randall, C.Riestra Menendez, S.Ritter, T.Rivero, M.Roblin, X.Rocca, R.Romatowski, J.Rydzewska, G.Saibeni, S.Salzberg, B.Sarles, H.Saunders, J.Savarino, E.V.Serclova, Z.Shchukina, O.Siegel, J.Soofi, N.Sparrow, M.Stokesberry, D.Suiter, D.Svorcan, P.Tkachev, A.Tsonev, N.Tünde, K.Ulbrych, J.Vanasek, T.Varga, M.Vermeire, S.Vicente Lidon, R.Weiss, M.L.Wesley, E.Winstead, N.Wojcik, K.Wypych, J.Zaltman, C.Zdena, Z.
Source
In: The Lancet. (The Lancet, 11 June 2022, 399(10342):2200-2211)
Subject
Language
English
ISSN
1474547X
01406736